Study Evaluating Infliximab to Prevent Cytokine Release Syndrome in Adults Receiving Teclistamab or Talquetamab for Relapsed or Refractory Multiple Myeloma

What this Trial Is About

Researchers are evaluating how well infliximab works to prevent cytokine release syndrome CRS during treatment with teclistamab or talquetamab in patients with relapsed or refractory multiple myeloma. CRS and neurologic toxicity are potential side effects of these treatments, causing inflammation and symptoms like changes in blood pressure, flu-like effects, and brain-related issues. Infliximab blocks a chemical messenger involved in inflammation and may help prevent CRS in this patient group. Participants receive infliximab through an intravenous IV infusion on day 1, administered two to four hours before standard treatment with teclistamab or talquetamab given subcutaneously SC on specified days. Treatment continues as long as there is no disease progression or unacceptable side effects. Before treatment, patients undergo a bone marrow biopsy and may have imaging scans such as x-rays or PET-CT. Blood samples are collected throughout the study for analysis. During the study, participants are monitored for CRS, neurologic toxicity, infections, anemia, neutropenia, thrombocytopenia, and overall response to treatment, primarily within the first 28 days. After treatment ends, patients are followed up at day 28. The study includes assessments like bone marrow biopsies, imaging, and blood tests to evaluate treatment effects and safety over the course of participation.

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma